Gilead Sciences Inc.
Gilead Sciences Reports Strong 2025 Financial Results
Summary
Gilead Sciences, Inc. announced its financial results for the quarter and year ended December 31, 2025, reporting a 5% increase in total fourth quarter 2025 revenues to $7.9 billion and a 2% increase in total full year 2025 revenues to $29.4 billion. The company's product sales excluding Veklury increased 4% year-over-year to $28.0 billion for the full year 2025. Key product sales included a 7% increase in Biktarvy sales to $14.3 billion for the full year. Gilead also provided 2026 financial guidance and discussed several product updates and pipeline advancements.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement